Business Context and Reporting Period
This Form 8-K, filed on December 19, 2011, reports events for Transdel Pharmaceuticals, Inc. (the "Company") occurring between October 7, 2011, and December 16, 2011. The Company emerged from a Chapter 11 bankruptcy case (dismissed December 9, 2011) following the termination of a proposed asset sale to Cardium Healthcare, Inc. The filing details a recapitalization and change in control involving DermaStar International, LLC ("DermaStar").
Key Financial Metrics and Capital Structure
- Debt Financing: Entered a Secured Line of Credit Agreement with DermaStar for up to $750,000. An initial advance of $150,000 was received on December 12, 2011. The loan accrues interest at 10% per annum and is secured by a blanket lien on all Company assets, including intellectual property.
- Equity Financing: Issued 10 shares of Series A Convertible Preferred Stock to DermaStar for $100,000. These shares carry a liquidation preference of $10,000 per share.
- Capitalization: Prior to the transaction, the Company had approximately 15,882,000 shares of Common Stock outstanding. The Series A Preferred Stock is convertible into 59,988,002 shares of Common Stock.
- Liquidity: Proceeds from the initial loan advance were used to satisfy administrative and priority claims, as well as legal and accounting fees.
Material Changes Versus Prior Period
- Bankruptcy Dismissal: The Chapter 11 Case was dismissed on December 9, 2011, ending the Company's bankruptcy proceedings.
- Termination of Asset Sale: The Company terminated the Asset Purchase Agreement with Cardium Healthcare, Inc., which had been denied approval by the Bankruptcy Court in July 2011.
- Change in Control: DermaStar acquired effective control of the Company. Upon full conversion of the Series A Preferred Stock (pending an amendment to the Certificate of Incorporation), DermaStar would hold approximately 79% of the voting securities.
- Management Changes: Effective December 16, 2011, Anthony S. Thornley resigned as a director, and Terry Nida resigned as Principal Executive Officer and Principal Financial Officer. Mark L. Baum and Dr. Robert J. Kammer (Managing Members of DermaStar) joined the Board of Directors.
Outlook, Risks, and Contingencies
- Share Authorization Risk: The Company currently lacks sufficient authorized Common Stock to convert all Series A Preferred Stock. DermaStar can currently convert only 5 of its 10 shares (approx. 65% ownership) until stockholders approve an amendment to increase authorized shares.
- Loan Acceleration Triggers: The Line of Credit may accelerate if there is a change in ownership of more than 20% of voting stock (excluding DermaStar purchases) or if the Company is named as a defendant in legal actions by current/former employees or directors.
- Preferred Stock Rights: Holders of Series A Preferred Stock vote on an "as-converted" basis and possess veto power over fundamental transactions, amendments to charter documents, and issuance of new debt or equity.
- Legal Releases: A Mutual General Release was executed with certain former and current employees, officers, and directors, releasing the Company from liability for actions occurring through the date of the release.
Investor Verification Checklist
- Verify the status of the proposed amendment to the Certificate of Incorporation to increase authorized shares, which is required for DermaStar to achieve full 79% ownership.
- Confirm the terms of the blanket security interest granted to DermaStar over all Company assets and intellectual property.
- Review the specific conditions precedent for future advances under the $750,000 Line of Credit.
- Assess the impact of the Mutual General Release on potential future litigation risks involving former management.
- Monitor the Company's ability to generate revenue or secure additional funding given the recent management turnover and post-bankruptcy status.